Navigation Links
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Date:8/19/2007

Third Phase II Trial Initiated by Myriad For Azixa(TM)

TARRYTOWN, N.Y., Aug. 17 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today reported on new clinical advancements for Azixa(TM)* (MPC-6827), a vascular disrupting agent licensed by the Company to Myriad Genetics, Inc. as part of an exclusive, worldwide development and commercialization agreement.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

Myriad announced yesterday that it has initiated a third Phase II clinical trial for Azixa in patients with non-small-cell lung cancer that has spread to the brain. The trial is designed to assess Azixa's safety profile and the extent to which it can improve the overall survival of these patients. Two additional Phase II trials for Azixa are underway in primary brain cancer and melanoma that has spread to the brain.

"We are pleased at the clinical advancement Myriad has reported on Azixa, and view it as further evidence of the commercial potential of the compound," stated Jack Talley, President and Chief Executive Officer. "We believe that the study of Azixa in this new indication affords EpiCept with an expanded opportunity to capitalize on the financial benefits associated with our agreement with Myriad, including milestone payments, sublicensing income and potentially future royalties if Azixa continues to progress successfully."

Myriad is responsible for the worldwide development and commercialization of Azixa and any drug candidate that is developed from the series of compounds licensed by EpiCept to Myriad in 2003. The agreement requires that Myriad make future licensing, research and milestone payments to EpiCept, as well as pay a portion of any sublicensing income and pay a royalty on product sales. EpiCept will earn a milestone payment upon the dosing of the first patient in a Phas
'/>"/>

SOURCE EpiCept Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... MADISON, Wis. , July 24, 2014 /PRNewswire/ ... provides specialty and compounded pharmaceuticals, announced that it ... sensitivity information unique to each individual based upon ... now possible by understanding the interaction between a ... "We,re very excited to provide this ...
(Date:7/24/2014)... , Germany , and ... -- , Exclusive global license ... for SF3B1 mutations, including next-generation sequencing (NGS) gene panels, ... to be targeted by new test, indicate favorable prognosis ... syndromes  QIAGEN sees potential for developing companion ...
(Date:7/24/2014)... -- Abaxis, Inc. (NasdaqGS: ABAX ), a medical ... financial results for the first fiscal quarter ended June ... Revenues of $47.5 million, up 10% over last year,s ... 50% over last year,s comparable quarter. Revenues ... up 20% over last year,s comparable quarter. , ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11
... EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany , ... for filing the New Drug Application (NDA) for Cladribine Tablets as a ... , , ... Review designation by the FDA, which means the review period for the ...
... , SHANGHAI , July ... WX ) today announced that RiskMetrics Group,s ISS Proxy Advisory ... has recommended that WuXi shareholders vote FOR Charles River,s proposed,acquisition ... Proxy,Governance, previously recommended that WuXi shareholders vote FOR the,transaction. , ...
Cached Medicine Technology:EMD Serono, Inc.: FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of MS 2EMD Serono, Inc.: FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of MS 3EMD Serono, Inc.: FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of MS 4EMD Serono, Inc.: FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of MS 5ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 2ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 3ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 4ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 5
(Date:7/26/2014)... July 26, 2014 According to the ... this is a comprehensive bodybuilding program that helps men ... anabolic steroids . The program also instructs men ... cardio. , Vkool reveals in its review that ... that can help men get ripped and jacked at ...
(Date:7/26/2014)... As the category creator and world leader ... Xoçai is to transform and improve individual ... products. One such unique element is XoVita™, a ... blueberries, an ingredient combination exclusive to Xoçai. This ... all of Xoçai products and provides a wide-ranging ...
(Date:7/25/2014)... 2014 PersonalInjurySolicitorsIreland, a legal claims ... people who have suffered from a variety of ... their new company, and a website, http://www.PersonalInjurySolicitorsIreland.com ... website explained, http://www.personalinjurysolicitorsireland.com/personal-injury-claims , the law firm ... the company is always on the client, and ...
(Date:7/25/2014)... In recent years, men have become more aware ... symptoms associated with age-related testosterone decline. Amid concerns about testosterone ... case study from Renew Man helps to shed ... using bioidentical hormones. , The case study centers around a ... himself beginning to feel the effects of age-related hormonal decline. ...
(Date:7/25/2014)... July 25, 2014 A federal judge ... in two DePuy Pinnacle hip lawsuits ( http://www.depuypinnacle-lawsuit.com/ ... the claims to go before a jury on September ... rendered on July 18th, U.S. District Judge Ed Kinkeade ... two Plaintiffs’ claims may proceed to trial against Johnson ...
Breaking Medicine News(10 mins):Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 2Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 3Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 2Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 3Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 4Health News:PersonalInjurySolicitorsIreland.com Announces the Launch of their New Company and Website 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4
... NEW YORK, March 25 As Americans get ... it,s important for men with type 2,diabetes to ... low testosterone than,non-diabetic men., Listen to this ... Registered journalists can access video, audio, text, graphics ...
... In a ceremony,attended by Ohio,s physician leaders, ... of the most sweeping physician-insurance industry,contract reform bills ... law, which will take effect in ninety days, ... the contracting process,fairness in contracting, and a standardized ...
... of a prevention effort , , TUESDAY, March 25 (HealthDay ... to prevent cancer can often be overstated in certain ... a new report claims. , The review, published in ... of the National Cancer Institute , suggests that some ...
... A new study reviewing 75 group-randomized cancer trials over ... those studies used appropriate statistical methods to analyze the ... reported that interventions to prevent disease or reduce cancer ... have been. , More than a third of the ...
... NEW YORK, March 25 North American Insurance,Leaders, Inc. ... of a majority,of the common stock of NAO entitled ... voted against the proposal to consummate a business,combination, as ... Since NAO will not be able to complete ...
... China, March 25 /Xinhua-PRNewswire/ -- China Medicine,Corporation ... "the Company"),a leading developer and distributor of ... medicines (TCM), nutritional and,dietary supplements, medical devices, ... conduct a conference call at 9:00 a.m. ...
Cached Medicine News:Health News:Governor Strickland Signs House Bill 125 Into Law 2Health News:Some Cancer Trials Overstate Findings, Analysis Claims 2Health News:Some Cancer Trials Overstate Findings, Analysis Claims 3Health News:Review of group-based cancer trials reveals flaws in studies' design and analysis 2Health News:Review of group-based cancer trials reveals flaws in studies' design and analysis 3Health News:China Medicine Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results 2Health News:China Medicine Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results 3
The Volk 30D is designed to provide the practitioner a wide field of view with a short working distance. This lens is excellent for use with small pupils....
Provides exceptional resolution and fundus scanning capability. Excellent for small pupil diagnosis and treatment....
... The Macula Plus® ... detailed observation of the ... macula. Use it with ... for detecting choroidal neovascular ...
... Iris Diagnostics iQ200 Sprint Automated Urine Microscopy ... to the iQ200 Series. The analyzer uses ... to classify urine particles into 12 categories ... eliminates most technologist time used to prepare ...
Medicine Products: